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AT A GLANCE COMMENTARY 44 
 45 
Scientific Knowledge on the Subject 46 
A large number of culture-dependent and -independent studies have revealed a significant 47 
anaerobic bioburden in the cystic fibrosis (CF) airways; however, the role of anaerobic 48 
  
bacteria in the pathogenesis of infection and inflammation in the CF airways remains largely 49 
underexplored. 50 
 51 
What This Study Adds to the Field 52 
In the current study we demonstrate a high prevalence of anaerobes in the airways of people 53 
with CF that increases with age. Short-chain fatty acids (SCFAs) were secreted by anaerobic 54 
bacteria in vitro and were also detected in vivo in CF bronchoalveolar lavage. SCFAs induced 55 
a significant IL-8 response in bronchial epithelial cells that was more pronounced in CF than 56 
normal bronchial epithelium. Receptors for SCFAs, GPR41 and GPR43, were both expressed 57 
in bronchial epithelial cells. However, only GPR41 was upregulated in CF compared to 58 
normal airway epithelium in vitro and in vivo. GPR41 upregulation was intrinsically driven 59 
by the lack of CFTR activity and endoplasmic reticulum stress and further corroborated by 60 
inflammatory stimuli. This study provides novel insight into the pathophysiological role of 61 
anaerobic bacteria in the CF airways. 62 
 63 
This article has an online supplement, which is accessible from this issue’s table of content 64 
online at www.atsjournals.org. 65 
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Abstract 66 
Rationale: Anaerobic bacteria are present in large numbers in the airways of people with 67 
cystic fibrosis (PWCF). In the gut, anaerobes produce short-chain fatty acids (SCFAs) that 68 
modulate immune/inflammatory processes.  69 
Objectives: To investigate the capacity of anaerobes to contribute to CF airway pathogenesis 70 
via SCFAs. 71 
Methods: Samples from 109 PWCF were processed using anaerobic microbiological culture 72 
with bacteria present identified by 16S RNA sequencing. SCFAs levels in anaerobe 73 
supernatants and bronchoalveolar lavage (BAL) were determined by gas chromatography. 74 
The mRNA and/or protein expression of SCFAs receptors, GPR41 and GPR43, in CF and 75 
non-CF bronchial brushings, and 16HBE14o- and CFBE41o- cells were evaluated using RT-76 
PCR, western blot, laser scanning cytometry and confocal microscopy. SCFAs-induced IL-8 77 
secretion was monitored by ELISA. 78 
Measurements and Main Results: Fifty seven of 109 (52.3 %) PWCF were anaerobe-positive. 79 
Prevalence increased with age, from 33.3% to 57.7% in PWCF under (n=24) and over 6 years 80 
(n=85). All evaluated anaerobes produced millimolar concentrations of SCFAs, including 81 
acetic, propionic and butyric acid. SCFAs levels were higher in BAL samples from adults 82 
than children. GPR41 levels were elevated in; CFBE41o- versus 16HBE14o- cells; CF versus 83 
non-CF bronchial brushings; 16HBE14o- cells after treatment with CFTR inhibitor 84 
CFTR(inh)-172, CF BAL, or inducers of endoplasmic reticulum stress. SCFAs induced a 85 
dose-dependent and pertussis toxin-sensitive IL-8 response in bronchial epithelial cells with a 86 
higher production of IL-8 in CFBE41o- than 16HBE14o- cells. 87 
Conclusions: This study illustrates that SCFAs contribute to excessive production of IL-8 in 88 
CF airways colonized with anaerobes via upregulated GPR41. 89 
 90 
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Introduction 95 
The main cause of morbidity and mortality in cystic fibrosis (CF) is respiratory failure due to 96 
persistent microbial infection and neutrophil-dominated inflammation (1, 2). CF airway 97 
infection is polymicrobial and bacteria such as Pseudomonas aeruginosa, Staphylococcus 98 
aureus, Haemophilus influenzae, and Burkholderia cepacia complex have been recognized as 99 
key pathogens in CF airway infection (3). The detection of bacterial pathogens in CF has 100 
widely depended on routine aerobic culture techniques. Consequently, the prevalence of 101 
anaerobic and other fastidious bacteria has remained largely understudied. With the 102 
implementation of enhanced culture and culture-independent molecular-based techniques, 103 
interest in the prevalence and potential pathogenic role of anaerobes has been sparked (4–6). 104 
Anaerobic bacteria are present in the airways of 66-91% people with CF (PWCF) (7, 8) in 105 
numbers equal to those of P. aeruginosa, a well-established pathogen in the CF airways (3, 106 
7). Studies exploring the role of anaerobes have failed to show a direct impact on airway 107 
function in CF (7, 8). However, more recent studies have associated decreasing CF airway 108 
microbial diversity, to which anaerobic bacteria contribute, with poorer lung function (9–11). 109 
Contrary to this, Prevotella intermedia was shown to induce a humoral immune response in 110 
PWCF and mediate an influx of neutrophils and macrophages thereby increasing CF airway 111 
inflammation (12). Furthermore, anaerobes belonging to the oropharyngeal flora have been 112 
shown to enhance the virulence of P. aeruginosa in a number of infection models (13–17). 113 
Anaerobic bacteria comprise an integral part of the normal gut microflora, where they 114 
produce copious amounts of short-chain fatty acids (SCFAs), including acetic, propionic and 115 
butyric acid (18). In addition to their role as fuel for intestinal epithelial cells, SCFAs 116 
modulate various processes, including cell proliferation and differentiation, hormone 117 
secretion, metabolic homeostasis and modulation of immune/inflammatory responses (18–23) 118 
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by binding to the recently deorphanized G protein-coupled receptors, GPR41 (FFAR3) and 119 
GPR43 (FFAR2) and by the inhibition of histone deacetylase (HDAC) (24–26).  120 
In the current study, we investigated the capacity of anaerobic bacteria, found in the CF 121 
airways, to induce an inflammatory response by the production of SCFAs. The results reveal 122 
that these anaerobes produce copious amounts of SCFAs that were also present in the 123 
bronchoalveolar lavage (BAL) of PWCF. SCFAs induced a dose-dependent and pertussis 124 
toxin (PTX)-sensitive IL-8 response in bronchial epithelium that was higher in CF when 125 
compared to normal bronchial epithelial cells. This effect coincided with increased GPR41 126 
expression in CF when compared to normal bronchial epithelial cells that was intrinsically 127 
driven by lack of CFTR activity and endoplasmic reticulum (ER) stress, in addition to the 128 
proinflammatory milieu of the CF airways. 129 
130 
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Methods 131 
Comprehensive detail on all methods, including Quantification of SCFA, Quantification of 132 
SCFAs Receptors, CF and non-CF Bronchial Epithelial Cell Culture and Treatments and 133 
Measurement of IL-8 is provided in the online supplement. 134 
 135 
Study population. A total of 109 PWCF (range 0-61, mean age 20.7 ± 12.1 years; 65 male, 136 
44 female) were recruited to this study. Seventy-three PWCF were attending Beaumont 137 
Hospital, Dublin (range 18-61, mean age 27.4 ± 8.2; 44 male, 29 female), 24 were attending 138 
Our Lady’s Children’s Hospital, Crumlin (range 0-6, mean age 3.5 ± 1.6; 11 male, 13 female) 139 
and 12 were attending Children's University Hospital Temple Street, Dublin (range 7-17, 140 
mean age 14.6 ± 2.4; 10 male, 2 female). CF was confirmed by sweat testing and/or 141 
genotyping. Only clinically stable PWCF were included in this study. Clinical stability was 142 
defined as no change in symptoms, forced expiratory volume in the first second (FEV1) 143 
within 10% of best value in the previous 6 months, and no new antibiotics started. Full 144 
informed consent was obtained from all participants or their parents prior to the collection of 145 
samples and ethical approval was obtained from Beaumont Hospital, Our Lady’s Children’s 146 
Hospital or Children's University Hospital Institutional Review Board. 147 
 148 
Collection and processing of sputum and BAL. Spontaneously expectorated sputum was 149 
collected in a sterile container that was placed into an Anaerogen™ Compact anaerobic 150 
pouch (Thermo Fisher Scientific, Waltham, MA, USA) and immediately transported to an 151 
anaerobic cabinet for further processing. BAL samples were obtained from individuals 152 
undergoing diagnostic or therapeutic fiber-optic bronchoscopy as part of routine care. In 153 
adults, 60 ml of sterile 0.9% NaCl was instilled into the right or left sub-segmental bronchi. 154 
In children, flexible fiber-optic bronchoscopy was performed via a laryngeal mask airway. To 155 
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prevent upper airway contamination suction was not performed until the tip of the 156 
bronchoscope was past the carina. During the procedure, 1 ml/kg of sterile 0.9% NaCl was 157 
instilled twice in the right middle lobe and twice in the lingula and all four samples were 158 
pooled. BAL intended for anaerobic bacterial isolation and identification was handled as 159 
described for sputum above and BAL samples intended for SCFAs determination were 160 
filtered through gauze and centrifuged at 500g for 10 min at 4°C. The microbiological culture 161 
and identification of bacteria in sputum and BAL were carried out as described previously 162 
(7). 163 
 164 
Bronchial brushing sample collection. All patients (control subjects and PWCF) were 165 
undergoing diagnostic or therapeutic fiber-optic bronchoscopy as part of routine care. 166 
Bronchial brushings were recovered as previously described (27). 167 
 168 
Statistical Analysis. Data were analyzed with GraphPad Prism 4.0 software (GraphPad 169 
Software, San Diego, CA). Unless stated otherwise, all data are presented as mean ± SEM 170 
and are representative of at least three independent experiments. Normal data were compared 171 
using the Student’s t-test, non-normal data were compared by Mann-Whitney U test and 172 
where appropriate ANOVA was performed. Differences were considered significant at P < 173 
0.05. 174 
175 
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Results 176 
 177 
Anaerobic bacteria are present in a high percentage of PWCF. To determine the 178 
prevalence of anaerobic bacteria in the CF airways, 80 sputum and 29 BAL samples from 109 179 
PWCF were collected and analyzed (one sample per patient). The presence of ≥1 obligate 180 
anaerobe was found in 57 of 109 analyzed samples (52.3 %). The most frequently detected 181 
obligate anaerobes belonged to the genera Prevotella (35.8 %), Actinomyces (16.5 %), 182 
Veillonella (8.3 %), and Fusobacterium (5.5 %) (Table E1) and the most commonly 183 
occurring aerobes (facultative anaerobes) belonged to the genus Pseudomonas (44.0 %), 184 
Staphylococcus (41.3 %) and Streptococcus (40.4 %), including S. anginosus, S. constellatus, 185 
S. intermedius, S. parasanguinis and S. sanguinis. The prevalence of obligate anaerobes was 186 
greater than that of P. aeruginosa (43.2%). Higher prevalence of anaerobes was observed in 187 
PWCF over 6 years of age (57.7 %, n = 85, mean age 25.6 ± 8.9 years, 54 males and 31 188 
females) compared to PWCF under 6 years of age (33.3 %, n = 24, mean age 3.5 ± 1.6 years, 189 
11 males and 13 females; Figure 1A), demonstrating that the anaerobic prevalence increases 190 
with age. Based on these data, four representative obligate anaerobes and one facultative 191 
anaerobe were selected for further work, namely Prevotella melaninogenica, Actinomyces 192 
odontolyticus, Veillonella parvula, Fusobacterium nucleatum, and Streptococcus sanguinis. 193 
 194 
Selected anaerobic strains secrete copious amounts of SCFAs in vitro. To investigate 195 
whether anaerobic bacteria found in the CF airway secrete SCFAs, bacterial supernatants 196 
from five representative species grown under anaerobic conditions were collected and 197 
analyzed using gas chromatography. ATCC and patient-isolated strains of all selected species 198 
secreted a variety of SCFAs in millimolar concentrations (Figure 1B). Each individual 199 
species had its own secretion profile which was identical for the ATCC and patient isolate 200 
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strain. For example, while A. odontolyticus and S. sanguinis secreted acetic acid, V. parvula 201 
and F. nucleatum displayed more complex SCFAs secretomes, consisting of acetic and 202 
propionic acid and acetic, propionic and butyric acid, respectively. P. melaninogenica, 203 
produced the highest number of SCFAs, including acetic, i-butyric, 2-methylbutyric and i-204 
valeric acid, albeit in lower concentrations. Of note, P. aeruginosa grown under anaerobic or 205 
aerobic conditions did not secrete any SCFAs (data not shown). These data suggest that 206 
anaerobic bacteria found in the CF airway produce copious amounts of SCFAs. 207 
 208 
SCFAs are present in the airways of PWCF and are elevated in adults when compared 209 
to children with CF. To investigate whether anaerobes produce SCFAs in the CF airway in 210 
vivo, BAL samples from adults (n = 11; mean age 29.2 ± 9.3 years; 3 males and 8 females) 211 
and children with CF (n = 7; mean age 4.0 ± 2.2 years; 2 males and 5 females) were collected 212 
and analyzed using gas chromatography. Six SCFAs detected in bacterial supernatants were 213 
also observed in µM concentration range in BAL samples from adult PWCF (Figure 1C). A 214 
significant increase in acetic (P < 0.001) was observed in BAL samples from adult PWCF 215 
when compared to children with CF. These results illustrate that SCFAs are present in the 216 
airways of PWCF and are elevated in adult PWCF compared to children with CF. 217 
 218 
IL-8 is elevated in BAL from adult PWCF when compared to children with CF and 219 
correlates with acetic acid. IL-8 is an inflammatory marker in the airways of PWCF that 220 
mediates neutrophil trafficking to the bronchial lumen (28). As evaluated with an IL-8 221 
ELISA, IL-8 was markedly increased in BAL samples from adult PWCF (n =10; mean age 222 
30.1 ± 9.7 years; 3 males and 7 females) compared to children with CF (n = 6; mean age 4.5 223 
± 1.9 years; 2 males and 4 females; Figure 1D). A correlation analysis was performed to 224 
investigate whether this phenomenon was associated with SCFAs levels in CF BAL. IL-8 225 
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levels displayed a strong correlation with acetic acid in BAL samples from children and 226 
adults with CF (n = 16, r2 = 0.6409, P = 0.002; Figure 1E). Similarly, a significant correlation 227 
was also observed between IL-8 and acetic acid in BAL samples from adult PWCF (n = 10, 228 
r2 = 0.4200, P = 0.0427). No significant correlation between IL-8 and other SCFAs in CF 229 
BAL was observed (data not shown). Collectively, these results showcase that elevated IL-8 230 
levels in CF BAL are associated with high levels of acetic acid in BAL. 231 
 232 
Anaerobe supernatants induce an inflammatory response in CF epithelial cells. 233 
CFBE41o- cells were treated with supernatants from representative species and monitored for 234 
IL-8 secretion using ELISA. All five strains induced a dose- and PTX-dependent IL-8 235 
response in CFBE41o- cells (Figure 2, Figure E1 and E2). The highest IL-8 response was 236 
observed with V. parvula and F. nucleatum supernatants which were shown to produce high 237 
amounts of acetic, propionic and butyric acid. Interestingly, the IL-8 response induced by V. 238 
parvula and F. nucleatum was equal or greater than that induced by major CF pathogens, S. 239 
aureus and P. aeruginosa. When CFBE41o- cells were treated with S. sanguinis or A. 240 
odontolyticus which secreted acetic acid only, a less pronounced IL-8 response was observed 241 
and higher concentrations of bacterial supernatant (5 and 10 %) were needed to achieve 242 
significant cytokine production (Figure E1). P. melaninogenica displayed an intermediate but 243 
significant impact on IL-8 production. Upon stimulation of 16HBE14o- cells with anaerobe 244 
supernatants, only F. nucleatum induced a significant IL-8 response over baseline levels 245 
(Figure 2). Furthermore, anaerobe-induced IL-8 responses in 16HBE14o- cells were 246 
strikingly lower when compared to CFBE41o- cells, suggesting that the CF epithelium is 247 
more susceptive to stimulation by anaerobe supernatants.  248 
 249 
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SCFAs generate a notable IL-8 response in CF epithelial cells. To elucidate whether 250 
SCFAs in anaerobe supernatants contribute to IL-8 secretion, bronchial epithelial cells were 251 
treated with SCFAs and analyzed for IL-8 secretion. The influence of SCFAs on cell viability 252 
was evaluated to exclude any SCFAs-induced cytotoxicity (Figure E3) and in the following 253 
experiments the cells were treated with non-toxic concentrations of SCFAs. All SCFAs, apart 254 
from 2-methylbutyric acid, induced a significant and a dose-dependent IL-8 response from 255 
CFBE41o- cells (Figure 3) with the potency rank order: butyric (EC50 = 0.170 mM, R
2 = 256 
0.8816) > i-valeric (EC50 = 1.0 mM, R
2 = 0.7711) > propionic (EC50 = 4.6 mM, R
2 = 0.9107) 257 
> acetic (EC50 = 15.5 mM, R
2 = 0.8443) > i-butyric acid (EC50 = 64 mM , R
2 = 0.8304). At 258 
the same time, no basal or SCFA-stimulated IL-1β levels were detected in CFBE41o- 259 
supernatants (data not shown). Additionally, a small but insignificant increase in SCFA-260 
induced IL-6 over baseline was observed in CFBE41o- supernatants (Figure E4). This 261 
response was markedly lower when compared to IL-8, confirming that IL-8 is the 262 
predominant pro-inflammatory cytokine induced by SCFAs in CF bronchial epithelial cells. 263 
When CFBE41o- cells were treated with a combination of SCFAs mimicking the complex 264 
SCFAs secretomes of P. melaninogenica, F. nucleatum and V. parvula, no synergistic effect 265 
on IL-8 secretion was observed (Figure E5). SCFAs also induced a dose-dependent IL-8 266 
response in 16HBE14o- cells (Figure 3); however, IL-8 secretion was significantly less 267 
pronounced in 16HBE14o- compared to CFBE41o- cells corroborating our earlier 268 
observations with anaerobe supernatants. These results confirm that SCFAs in anaerobe 269 
supernatants are at least in part responsible for the inflammatory response in bronchial 270 
epithelial cells in vitro. Of note, upon incubation of representative SCFAs (acetic, propionic 271 
and butyric acid) with human serum albumin or alpha-1 antitrypsin no changes in intrinsic 272 
fluorescence of either proteins were observed (Figure E6), suggesting that SCFAs do not bind 273 
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human serum albumin or alpha-1 antitrypsin. Moreover, the latter also failed to attenuate the 274 
SCFAs-induced IL-8 response in CFBE41o- cells (Figure E7).  275 
 276 
SCFAs-mediated release of IL-8 by CFBE41o- cells is GPR41-dependent. Previous 277 
studies have shown that GPR41 couples exclusively through the PTX-sensitive Gαi/o family, 278 
whereas GPR43 displays dual coupling through Gαi/o and PTX-insensitive Gαq protein 279 
families (24, 25). To explore whether SCFAs-mediated IL-8 release was indeed mediated by 280 
SCFAs receptors, CFBE41o- cells were treated with PTX prior to SCFAs. PTX (250 ng/ml) 281 
significantly attenuated IL-8 secretion in CFBE41o- cells induced by all evaluated SCFAs 282 
(Figure 4A). Higher PTX concentrations (500 and 1000 ng/ml) did not fully restore the IL-8 283 
baseline levels (Figure E8). These data suggest the involvement of PTX-sensitive receptors 284 
GPR41 and GPR43 in SCFAs-mediated cytokine response in CFBE41o- cells. 285 
To further confirm the involvement of GPR41 in SCFA-mediated IL-8 response, a small 286 
interfering RNA (siRNA) knockdown approach was employed. siRNA (80 nM) -mediated 287 
knockdown of GPR41 by the was confirmed using RT-PCR and western blot analysis 48 h 288 
after transfection (Figure 4B and 4C). Even a partial reduction of GPR41 protein expression 289 
(~50 %) was sufficient to significantly inhibit IL-8 production induced by acetic (10 mM), 290 
propionic (1 mM) and butyric acid (1 mM; Figure 4D). Collectively, these data corroborate 291 
the involvement of GPR41 in SCFA-mediated IL-8 release by CF bronchial epithelial cells. 292 
 293 
GPR41 expression is increased in CF when compared to normal bronchial epithelial 294 
cells. To confirm the expression of SCFAs receptors in human bronchial epithelium, mRNA 295 
and protein levels of GPR41 and GPR43 were evaluated. Western blot analysis revealed that 296 
the GPR41 receptor was expressed by both 16HBE14o- and CFBE41o- cells, with 297 
significantly higher protein expression in CFBE41o- than in 16HBE14o- cells (P < 0.001; 298 
12 
 
Figure 5A). GPR43 was expressed in 16HBE14o- and CFBE41o- cells at equivalent levels 299 
(Figure 5A). The cell surface expression of SCFAs receptors was further examined with laser 300 
scanning cytometry and confocal microscopy. Staining for the GPR41 receptor was 301 
significantly increased on the surface of CFBE41o- compared to 16HBE14o- cells as 302 
assessed with laser scanning cytometry (55.5 ± 19.5%, P < 0.001; Figure 5B). Although both 303 
cell lines displayed intracellular staining for GPR41 receptor as visualized with confocal 304 
microscopy (Figure 5C), a significant increase in co-localization of the GPR41 receptor with 305 
the plasma membrane marker, Na/K-ATPase, was observed in CFBE41o- (11.9 ± 2.0%) 306 
compared to 16HBE14o- (6.9 ± 1.1%, P = 0.0434) cells. No differences in GPR43 cell 307 
surface expression were detected in 16HBE14o- and CFBE41o- cells when analyzed with 308 
laser scanning cytometry or confocal microscopy (Figure E11). These results suggest that 309 
while GPR41 and GPR43 are both present in bronchial epithelial cells, only GPR41 is 310 
upregulated at the surface of CF epithelial cells when compared to normal bronchial 311 
epithelial cells.  312 
To investigate whether GPR41 mRNA was also increased in CFBE41o- cells, qRT-PCR was 313 
performed. GPR41 mRNA levels were significantly increased in CFBE41o- compared to 314 
16HBE14o- cells (P < 0.001; Figure 5D). The in vitro trend was also observed in vivo as an 315 
increase in GPR41 mRNA levels in bronchial brushings from PWCF compared to non-CF 316 
controls (P = 0.0064; Figure 5E). 317 
 318 
Endoplasmic reticulum stress upregulates GPR41 expression in CF bronchial epithelial 319 
cells in vitro. Previous studies have associated dysfunctional cystic fibrosis transmembrane 320 
conductance regulator (CFTR) with endoplasmic reticulum (ER) stress and activation of the 321 
unfolded protein response (UPR) (29). To elucidate whether the latter could have an impact 322 
on GPR41 expression, 16HBE14o- cells were treated with tunicamycin (2 µg/ml), 323 
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thapsigargin (2 µM) or dithiothreitol (DTT,1 mM), well established inducers of ER stress and 324 
UPR (30). ER stress and UPR induction by these compounds was confirmed by monitoring 325 
the expression of glucose-regulated protein (GRP) 78 and GRP 94 (Figure E10). 326 
Tunicamycin and thapsigargin significantly increased GPR41 protein levels in 16HBE14o- 327 
cells (P = 0.0297 and P = 0.0198, respectively; Figure 6A) These data suggest that ER stress 328 
and UPR may have a role in the GPR41 upregulation in CF bronchial epithelial cells. 329 
 330 
Dysfunctional CFTR and the inflammatory CF environment promote GPR41 331 
upregulation in CF bronchial epithelial cells in vitro. To explore the possibility that 332 
GPR41 upregulation in the CF airway epithelium could also be associated with reduced 333 
CFTR activity, 16HBE14o- cells were treated with a CFTR inhibitor, CFTR(inh)-172 (10 334 
µM), and subsequently evaluated for GPR41 mRNA expression. CFTR inhibition 335 
significantly increased GPR41 mRNA levels in 16HBE14o- cells (P = 0.0166; Figure 6B) 336 
matching them to levels found in CFBE41o- cells (Figure 5). Similarly, 10% CF BAL caused 337 
a significant upregulation of GPR41 mRNA in 16HBE14o- cells (P < 0.001; Figure 6B). 338 
These findings were translated to the protein level, as both CFTR(inh)-172 and 10% CF BAL 339 
significantly elevated GPR41 protein levels in 16HBE14o- cells (P = 0.0233 and P = 0.0098, 340 
respectively; Figure 6C). Similarly, GlyH-101, another inhibitor of CFTR also increased 341 
GPR41 protein levels (data not shown). These results imply that reduced CFTR activity may 342 
be associated with GPR41 upregulation in CF bronchial epithelial cells in vitro, an effect that 343 
is also driven by the inflammatory CF airway milieu. 344 
345 
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Discussion 346 
Recent advances in culture-independent molecular techniques for bacterial identification have 347 
sparked a renewed interest in the role of anaerobic bacteria in the CF airways. Therefore, we 348 
aimed to explore the contribution of anaerobes via SCFAs to the pathogenesis of CF airway 349 
disease. In the current study, we show that anaerobic bacteria commonly found in the CF 350 
airways secrete SCFAs in vitro and in vivo, and by acting through GPR41 and GPR43, 351 
mediate IL-8 release promoting an inflammatory response in the CF airway. 352 
Similar to previous studies (7, 8, 16) our cohort of PWCF displayed a high prevalence of 353 
anaerobic bacteria (52.3 %). This number was greater than that of P. aeruginosa (43.2 %), an 354 
established CF airway pathogen, confirming that anaerobes are prevalent in the CF airways, 355 
and may play a role during the course of the disease. Indeed, the percentage of PWCF 356 
positive for anaerobes increased with age. Five representative species, that were selected 357 
based on their prevalence, secreted high quantities of SCFAs, with each displaying a distinct 358 
SCFA secretome (Figure 1B). SCFAs were also detected in CF BAL and were elevated in 359 
BAL samples from adult PWCF compared to children with CF (Figure 1C). This suggests 360 
that alongside anaerobes, SCFAs also increase with age. Although SCFAs were previously 361 
studied in the context of allergic airway inflammation (31), to our knowledge, this is the first 362 
report proving the presence of SCFAs in the lower airways. 363 
CF airway disease is characterized by an exaggerated neutrophil influx that plays a key role 364 
in tissue damage and disease progression (32). We have previously shown that IL-8, a potent 365 
neutrophil chemotactic agent, is readily secreted from CF airway epithelium by various 366 
stimuli (33–35) and is found in high concentrations in CF BAL (28). Anaerobe supernatants 367 
induced a potent and dose-dependent IL-8 response that was more pronounced in CF than in 368 
normal bronchial epithelium (Figure 2 and Figure E11). Similarly, SCFAs generated a dose-369 
dependent IL-8 response in bronchial epithelial cells that was higher in CF than in normal 370 
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bronchial epithelial cells (Figure 3), suggesting that SCFAs in anaerobe supernatants 371 
contribute to the IL-8 response and may have a detrimental role in the CF airways by 372 
promoting neutrophil mobilization. 373 
In addition to the activation of airway epithelial cells to produce cytokines, SCFAs are known 374 
to display a plethora of other effects. SCFAs were recently shown to act as chemotactic 375 
agents for neutrophils via GPR43 (36). At the same time, butyric acid was also reported to 376 
impair neutrophil reactive oxygen species production, phagocytosis and microbial killing 377 
(37). This suggests that in addition to IL-8-mediated recruitment of neutrophils, SCFAs may 378 
display a direct effect on neutrophil migration to the CF airways and their function. 379 
Both SCFAs receptors, GPR41 and GPR43, couple to the PTX-sensitive Gαi/o family of 380 
proteins, but only GPR43 also couples to the PTX-insensitive Gαq family of proteins (24, 25). 381 
PTX blocks the signaling mediated by Gαi/o proteins (38) and PTX treatment significantly 382 
reduced the SCFAs-mediated IL-8 response (Figure 4) confirming that SCFAs mediate their 383 
effects via SCFAs receptors GPR41 and GPR43. However, increasing the concentration of 384 
PTX did not return the basal levels of IL-8 production after stimulation by propionic and 385 
butyric (Figure E8). Propionic and butyric are well established inhibitors of HDAC (38) and 386 
previous studies have shown that butyric acid induces an IL-8 response in human intestinal 387 
epithelial cells by inhibiting HDAC activity and promoting histone acetylation (26). 388 
Therefore, SCFA-induced IL-8 response in bronchial epithelial cells may also be mediated by 389 
HDAC inhibition in addition to SCFAs receptors. 390 
GPR41 expression is increased in CF bronchial epithelium in vitro and in vivo (Figure 5) and 391 
the mechanism of upregulation was subsequently investigated. F508del CFTR is the most 392 
common cause of CF. It causes misfolding of CFTR and its subsequent degradation after 393 
synthesis leading to a lack of the functional CFTR on the cell surface (39). Treatment with 394 
CFTR(inh)-172, a CFTR inhibitor, increased mRNA and protein levels of GPR41 in 395 
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16HBE14o- cells (Figure 6B and 6C), suggesting that the lack of CFTR activity could be 396 
associated with GPR41 upregulation in CF bronchial epithelial cells and that the mechanism 397 
could be related to defective chloride ion and/or bicarbonate conductance. Previously, we 398 
have demonstrated altered expression of microRNAs (miRNAs) in CF (27). miR-182, miR-399 
23b and miR-544 were shown to be decreased in CF bronchial brushings (27), and were 400 
identified to target GPR41 mRNA using various miRNA target prediction databases (40, 41). 401 
However, overexpression of these miRNAs failed to reduce GPR41 mRNA and protein 402 
expression in CFBE41o- cells (data not shown) excluding the possibility of regulation of 403 
GPR41 expression by these miRNAs. Accumulation of misfolded F508del CFTR in the ER 404 
causes ER stress that activates UPR, a signal transduction pathway to alleviate this stress and 405 
restore ER homeostasis (29, 42, 43). Exposure of 16HBE14o- cells to tunicamycin, 406 
thapsigargin or DTT, well-known inducers of ER stress and UPR, increased protein 407 
expression of GPR41 (Figure 6A), implying that the ER stress and UPR may 408 
also,independent of CFTR activity, contribute to GPR41 upregulation. Lastly, the CF airway 409 
harbors high concentrations of proinflammatory markers, including proteases and 410 
chemokines (28). Treatment of 16HBE14o- cells with CF BAL increased GPR41 mRNA and 411 
protein levels (Figure 6B and 6C) suggesting that in addition to intrinsic upregulation of 412 
GPR41 in CF, the latter could further be corroborated by the inflammatory milieu of the CF 413 
airways.  414 
In conclusion, we propose a novel mechanism by which anaerobic bacteria, through the 415 
production of SCFAs, contribute to the inflammatory environment in the CF airways in this 416 
way, potentially amplifying mobilization of neutrophils, tissue destruction and disease 417 
progression. This data suggests that eradication of anaerobes in PWCF may be beneficial in 418 
order to resolve the excessive inflammation brought on by these microorganisms. 419 
420 
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Figure legends 556 
 557 
Figure 1. Anaerobic species are found in high numbers in the CF airways and secrete 558 
copious amounts of SCFAs in vitro and in vivo. (A) The percentage of anaerobe-positive 559 
cultures in children with CF up to 6 years of age (n = 24; mean age 3.5 ± 1.6 years; 11 males 560 
and 13 females) and people with CF over the age of 7 (n = 85; mean age 25.6 ± 8.9 years; 54 561 
males and 31 females). Sputum or BAL samples from 109 PWCF were collected and 562 
screened for the presence of anaerobic bacteria as stated in materials and methods. Only four 563 
genera of the most frequent obligate anaerobes (Prevotella, Actinomyces, Veillonella, and 564 
Fusobacterium) and the most commonly occurring aerobes (facultative anaerobes) belonging 565 
to the genera Pseudomonas, Staphylococcus and Streptococcus are shown for clarity reasons. 566 
 (B) SCFAs levels in bacterial supernatants from ATCC and patient isolate strains of P. 567 
melaninogenica, A. odontolyticus, V. parvula, F. nucleatum and S. sanguinis as determined 568 
by gas chromatography. Data are presented as means ± SEM (n ≥ 3). (C) SCFAs levels in 569 
BAL samples from children with CF (n = 7; mean age 4.0 ± 2.2 years; 2 males and 5 females) 570 
and adults with CF (n = 11; mean age 29.2 ± 9.3 years; 3 males and 8 females). (D) IL-8 571 
levels in BAL samples from children with CF (n = 6; mean age 4.5 ± 1.9 years; 2 males and 4 572 
females) and adults with CF (n =10; mean age 30.1 ± 9.7 years; 3 males and 7 females) as 573 
evaluated with an IL-8 ELISA. (E) Correlation between IL-8 and acetic acid in BAL samples 574 
from people with CF (n = 16, r2 = 0.6409, P = 0.002). ** P ≤ 0.01, *** P ≤ 0.001.  575 
 576 
Figure 2. Supernatants from anaerobic bacteria promote a pro-inflammatory response 577 
in CF airway epithelial cells. 16HBE14o- and CFBE41o- cells were treated with 5 % 578 
bacterial supernatants or growth medium as control for 24 h and IL-8 secretion was assessed 579 
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with ELISA. All data are presented as means ± SEM of at least three independent 580 
experiments. ** P ≤ 0.01, *** P ≤ 0.001. 581 
 582 
Figure 3. Short-chain fatty acids induce a dose-dependent IL-8 response in bronchial 583 
epithelial cells. 16HBE14o- and CFBE41o- cells were treated with increasing concentrations 584 
of SCFAs for 24 h and monitored for IL-8 production using ELISA. All data are presented as 585 
means ± SEM of at least three independent experiments. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 586 
0.001. 587 
 588 
Figure 4. Pertussis toxin and GPR41 siRNA attenuate SCFAs-mediated IL-8 secretion 589 
in CF bronchial epithelial cells. (A) CFBE41o- cells were treated with pertussis toxin (PTX; 590 
250 ng/ml) and increasing concentrations of SCFAs for 24 h. Afterwards, cell supernatants 591 
were monitored for IL-8 secretion using ELISA. CFBE41o- cells were transfected with 592 
GPR41 or control siRNA and were evaluated for GPR41 mRNA and protein levels 48 h after 593 
transfection using qRT-PCR and western blot analysis, respectively. (B) mRNA expression 594 
of GPR41 relative to GAPDH was determined using the 2(–∆∆Ct) method and presented as fold 595 
differences. (C) Whole cell lysates were separated by 12.5 % SDS-PAGE, transferred to a 596 
PVDF membrane and detected with anti-GPR41 antibody. Signal intensities of all bands were 597 
quantified by densitometry and normalized against GAPDH that served as loading control. 598 
Bar graph depicts densitometric analysis of GPR41 expression. All data are presented as 599 
means ± SEM (n ≥ 3). (D) CFBE41o- cells were transfected with GPR41 or control siRNA 600 
(80 nM) 24 h before treatment with acetic (10 mM), propionic (1 mM) and butyric acid (1 601 
mM) for additional 24 h. Cell supernatants were monitored for IL-8 secretion using ELISA. 602 
The results shown are representative of three independent experiments. * P ≤ 0.05, ** P ≤ 603 
0.01, *** P ≤ 0.001. 604 
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 605 
Figure 5. Short-chain fatty acid receptor GPR41 is upregulated at the surface of CF 606 
bronchial epithelial cells. (A) A representative western blot depicting GPR41 and GPR43 607 
protein expression in 16HBE14o- and CFBE41o- cells. Whole cell lysates were separated by 608 
12.5 % SDS-PAGE, transferred to a PVDF membrane and detected with anti-GPR41 or 609 
GPR43 antibodies. Signal intensities of all bands were quantified by densitometry and 610 
normalized against GAPDH that served as loading control. Bar graph depicts densitometric 611 
analysis of GPR41 expression in 16HBE14o- and CFBE41o- cells. Data are shown as means 612 
± SEM (n ≥ 3). (B) GPR41 cell surface staining was analyzed in CFBE41o- and 16HBE14o- 613 
cells using LSC as stated in methods. Histograms, representative of three independent 614 
experiments are shown. Inlet values represent a fold increase in mean fluorescence intensity 615 
between cells stained with primary anti-GPR41 and secondary antibody (black line) and 616 
control cells stained only with the secondary antibody (grey line). (C) 16HBE14o- or 617 
CFBE41o- cells were grown on coverslips and probed with anti-GPR41 and anti-Na/K-618 
ATPase antibody followed by FITC-labeled and Alexa Fluor 568 secondary antibody, 619 
respectively. Controls were labeled with secondary antibodies only and are shown in Figure 620 
E11. Cell nuclei were visualized using DAPI (blue), GPR41 and Na/K-ATPase were 621 
visualized as green and red fluorescence, and colocalization is shown in white. Images shown 622 
are representative of three independent experiments. Scale bar, 5 μm. (D) qRT-PCR was 623 
performed in vitro using CFBE41o- and 16HBE14o- epithelial cells and (E) in vivo using 624 
bronchial brushings from PWCF (n = 3, mean age 23.0 ± 4.0 years, 2 males and 1 female) 625 
and non-CF controls (n = 3, mean age 56.3 ± 9.5 years, 3 females). Expression of GPR41 626 
relative to GAPDH was determined using the 2(–∆∆Ct) method and presented as fold 627 
differences. Data are presented as means ± SEM (n ≥ 3). ** P ≤ 0.01, *** P ≤ 0.001. 628 
 629 
28 
 
Figure 6. The mechanism of GPR41 upregulation in CF bronchial epithelial cells. (A) 630 
16HBE14o- cells were treated with thapsigargin (2 µM), tunicamycin (2 µg/ml) or DTT (1 631 
mM) for 24 h and the GPR41 protein levels were evaluated by western blot analysis. Whole 632 
cell lysates were separated by 12.5 % SDS-PAGE, transferred to a PVDF membrane and 633 
detected with anti-GPR41 antibody. Signal intensities of all bands were quantified by 634 
densitometry and normalized against GAPDH that served as loading control. Bar graph 635 
depicts densitometric analysis of the GPR41 expression. (B) 16HBE14o- cells were treated 636 
with CFTR(inh)-172 (10 μM) or 10% CF BAL for 24 and 6 h, respectively and the GPR41 637 
mRNA levels were evaluated using qRT-PCR as described in materials and methods. 638 
Expression of GPR41 relative to GAPDH was determined using the 2(–∆∆Ct) method and 639 
presented as fold differences. (C) 16HBE14o- cells were treated with CFTR(inh)-172 (20 640 
μM) for 48 h or 10% CF BAL for 24 h and GPR41 protein levels were evaluated with 641 
western blot analysis as above. Data are presented as means ± SEM of at least three 642 
independent experiments. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001. 643 
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